27
Sat, May
7 New Articles

AstraZeneca announced that the US FDA has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR TKI therapy.

More Articles ...

Sign up via our free email subscription service to receive notifications when new information is available.
captcha